{
    "organizations": [],
    "uuid": "5df5b6fafbd8fcb7b8934fdca504b31d2d81ce64",
    "author": "",
    "url": "https://www.reuters.com/article/brief-biomarin-pharmaceutical-q1-gaap-lo/brief-biomarin-pharmaceutical-q1-gaap-loss-per-share-0-26-idUSL8N1S295I",
    "ord_in_thread": 0,
    "title": "BRIEF-Biomarin Pharmaceutical Q1 GAAP Loss Per Share $0.26",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Biomarin Pharmaceutical Inc:\n* BIOMARIN ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS * Q1 REVENUE $373.4 MILLION VERSUS I/B/E/S VIEW $348.7 MILLION\n* Q1 GAAP LOSS PER SHARE $0.26 * Q1 EARNINGS PER SHARE VIEW $-0.17 â€” THOMSON REUTERS I/B/E/S\n* SEES FY 2018 REVENUE ABOUT $1.5 BILLION * AS OF MARCH 31, 2018, BIOMARIN HAD CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALING ABOUT $1.7 BILLION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-26T00:56:00.000+03:00",
    "crawled": "2018-04-26T01:04:31.001+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "biomarin",
        "pharmaceutical",
        "inc",
        "biomarin",
        "announces",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "revenue",
        "million",
        "versus",
        "view",
        "million",
        "q1",
        "gaap",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "see",
        "fy",
        "revenue",
        "billion",
        "march",
        "biomarin",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "totaling",
        "billion",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}